Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2010. The report serves as a notification of transactions involving directors or persons discharging managerial responsibility, specifically regarding the GlaxoSmithKline 2009 Deferred Annual Bonus Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific share transaction event rather than general financial performance.
Material Changes
On July 9, 2010, Mr. A P Witty's notional interest in Ordinary shares increased following the re-investment of dividends paid on July 8, 2010. The transaction details are as follows:
- Share Price: £11.18 per share
- Acquisition (Personal Contribution): 326 Ordinary shares
- Acquisition (Company Contribution): 326 Ordinary shares
Guidance, Outlook, and Risks
The filing does not contain management commentary, future guidance, or risk factors. It notes that notional dividends accrued will be paid out in proportion to the percentage of deferred annual bonus holdings that vest after the end of the relevant three-year measurement period. The transaction was notified in accordance with Disclosure and Transparency Rules 3.1.4R(1)(a).
Investor Verification Points
- Verify the vesting schedule and conditions for the 2009 Deferred Annual Bonus Plan.
- Confirm the total notional shareholding of Mr. A P Witty post-transaction.
- Review the dividend payment date of July 8, 2010, to validate the re-investment timing.